Compare Citius Pharmaceuticals Inc (CTXR) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while First Trust Cloud Computing ETF trades at $137.03. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SKYY | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | — |
52-Week High | $1.82 | $155.17 |
52-Week Low | $0.53 | $104.16 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
SKYY (First Trust Cloud Computing ETF) trades at $139.99 with a slight 0.16% daily gain, showing bullish technical momentum with strong moving average support. The ETF benefits from ongoing technology sector inflows and enterprise cloud adoption trends. Recent news highlights continued institutional interest in cloud computing ETFs as hyperscalers pivot to AI-first platforms.
The outlook remains positive given strong technical indicators and sector tailwinds, though investors should monitor potential overbought conditions. Key risks include technology sector volatility and competitive ETF offerings. Analyst coverage suggests sustained interest in cloud computing exposure amid digital transformation acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
